SIM01 showed promising results for Long COVID symptom relief, highlighting the role of the gut microbiome in recovery

INTRODUCTION - The lingering burden of Long COVID

Since the emergence of COVID-19 in late 2019, the virus has left a lasting mark on global health. According to the World Health Organization, more than 770 million people worldwide have been infected, and over seven million lives have been lost to the disease. 1 While some people experience only mild cold-like symptoms, others develop severe respiratory or systemic complications. ²

As vaccination campaigns helped reduce the burden of acute infection, another challenge became increasingly clear: Long COVID. Also known as post-COVID syndrome, this condition refers to symptoms that continue for weeks or even months after the virus itself has cleared. ³ Current estimates suggest that Long COVID may affect 10 to 30 percent of COVID survivors, representing at least 65 million people globally. ⁴ ⁵

The symptoms of Long COVID are wide-ranging and can have a major impact on quality of life. Common problems include fatigue, memory loss, difficulty concentrating, gastrointestinal upset, and general unwellness. ⁶ In the United States and elsewhere, Long COVID continues to place a heavy burden on individuals, families, and healthcare systems, particularly among working-age adults trying to return to normal life.

Long COVID symptoms

In response, researchers have been exploring new strategies that may help support recovery, including microbiome-targeted approaches such as probiotics and synbiotics for Long COVID support. Among these, a promising synbiotic preparation known as SIM01 has shown potential in helping restore gut microbiome balance and reduce symptom burden.

Understanding synbiotics - more than just probiotics

Synbiotics combine probiotics and prebiotics in one formula. While probiotics are beneficial live microorganisms that help support a balanced gut microbiome, prebiotics are the fibers that nourish them and encourage their growth. Together, synbiotics work in a complementary way to support gut health and immune resilience.

During the COVID-19 pandemic, emerging studies highlighted the potential of microbiome-targeted strategies in supporting immune function and reducing inflammation. Synbiotics may contribute to recovery support by improving intestinal barrier function, modulating immune responses, and limiting pathogen invasion. ⁷ These findings sparked interest in synbiotic preparations not only for the active phase of infection, but also during recovery, when immune and gut health may still be under strain. Among the different gut-focused approaches being explored, synbiotics stand out as a promising and generally well-tolerated option.

SIM01 - a clinically developed synbiotic preparation

During the peak of the COVID-19 pandemic, researchers observed that patients with severe symptoms often showed clear signs of gut microbiome disruption, including lower levels of beneficial bacteria and an overgrowth of less favorable species. ⁸

Using advanced metagenomics, AI-driven analysis, and large-scale fecal sample data, scientists compared the gut microbial profiles of hospitalized COVID-19 patients with those of healthy individuals. They identified a group of health-associated bacteria that were consistently more abundant in the healthy group.

From this group, three food-grade probiotic strains were carefully selected. These strains had an established safety profile and clinically validated health benefits. ⁹ They were then combined with three complementary prebiotics and encapsulated using a world-patented Italian microencapsulation technology (WO2013114185A1), designed to help the bacteria survive stomach acid and reach the colon alive for optimal colonization.

In a hospital-based clinical study, COVID-19 patients who received SIM01 alongside standard treatment recovered more quickly than those treated with medication alone. Within two weeks, they experienced greater symptom relief, significantly lower inflammatory markers, improved antibody responses, and full resolution of gastrointestinal symptoms such as diarrhea and abdominal pain. ¹⁰

These encouraging findings laid the groundwork for further research into the potential role of SIM01 in supporting people beyond the acute phase of infection, including those living with Long COVID.

The landmark clinical study in The Lancet Infectious Diseases

To rigorously evaluate the potential of SIM01 in Long COVID support, a landmark randomized, double-blind, placebo-controlled clinical trial was conducted and published in The Lancet Infectious Diseases in March 2024. 11 This large-scale study aimed to examine whether restoring the gut microbiota with a synbiotic preparation could help relieve the persistent symptoms associated with post-acute COVID-19 syndrome, or PACS.

The study enrolled 463 adults with PACS, defined as the presence of one or more persistent symptoms for more than four weeks after SARS-CoV-2 infection. Participants were randomly assigned to receive either the SIM01 synbiotic formula or a placebo (vitamin C), twice daily, over a six-month period. The SIM01 group received a microencapsulated synbiotic combination containing three Bifidobacterium strains (B. adolescentis, B. bifidum, and B. longum) together with three prebiotics.

Symptom improvement was assessed using the PACSQ-14 questionnaire, a validated tool that measures 14 common Long COVID symptoms, including fatigue, memory loss, difficulty concentrating, gastrointestinal discomfort, and general unwellness. A positive response was defined as improvement in at least two symptoms, considered sufficient by the participant to resume normal daily activities.

At six months, a significantly higher proportion of participants in the SIM01 group (60.5%) reported clinically meaningful symptom relief compared with the placebo group (41.5%). Most notably, SIM01 use was associated with significant improvements in five of the most burdensome symptoms:

• Fatigue
• Memory loss
• Difficulty concentrating
• Gastrointestinal upset
• General unwellness
  

1. Digestive problems
SIM01 group had significantly higher proportion of subjects with improved symptoms

2. Fatigue
SIM01 group had significantly higher proportion subjects with improved symptoms

3. Difficulty in concentration
SIM01 group had significantly higher proportion subjects with improved symptoms

4. Memory problem 
SIM01 group had significantly higher proportion subjects with improved symptoms

5. General Unwellness
SIM01 group had significantly higher proportion subjects with improved symptoms

The formulation was also well tolerated, with similar rates of mild and transient adverse events reported in both groups.

This clinical trial provides high-quality evidence that SIM01, a clinically studied synbiotic preparation, may help reduce the symptom burden of Long COVID and supports its role as a promising microbiome-targeted approach.

Why gut health matters in COVID recovery

The findings from the trial go beyond symptom relief and offer compelling evidence that restoring the gut microbiome may play an important role in Long COVID recovery. ¹¹ Earlier observational studies had already shown that both acute and post-acute COVID-19 are associated with significant gut dysbiosis, marked by reduced microbial diversity, lower levels of beneficial bacteria, and an overrepresentation of potentially harmful species.

At baseline, participants in the study showed low levels of short-chain fatty acid (SCFA)-producing bacteria and a high abundance of potential pathogens such as Klebsiella pneumoniae, K. variicola, Parabacteroides merdae, and Ruminococcus gnavus. These microbial patterns are known to contribute to inflammation and poor immune regulation.

After six months of SIM01 synbiotic supplementation, metagenomic analysis showed a significant restoration of microbial diversity and function. Researchers found a notable increase not only in the supplemented probiotic strains, but also in other beneficial taxa, including Bifidobacterium pseudocatenulatum, Roseburia intestinalis, Roseburia hominis, Faecalibacterium prausnitzii, and Akkermansia muciniphila. At the same time, the relative abundance of harmful bacteria and antimicrobial resistance genes declined.

Faecal microbiome composition at species level in participants receiving SIM01 versus placebo after six months, analysed using MaAsLin2. A false discovery rate (FDR) below 0.05 was considered statistically significant.
Red dots indicate bacterial species significantly enriched in the SIM01 group, while blue dots highlight species enriched in the placebo group.

Importantly, microbial functional pathways related to SCFA biosynthesis were significantly upregulated in the SIM01 group. This metabolic shift suggests increased production of butyrate and acetate, two key metabolites involved in immune modulation, gut barrier integrity, and energy metabolism.

Correlation analyses in the study also showed that increases in specific bacterial species were linked with symptom improvement. For example, a rise in B. adolescentis correlated with reductions in fatigue, memory loss, and gastrointestinal discomfort; B. bifidum was associated with improvements in fatigue and general unwellness; and B. longum was linked to better concentration.

Together, these findings strengthen the link between gut health and systemic recovery and support the biological plausibility that targeted synbiotic supplementation may help relieve Long COVID symptoms by improving the gut microbiome.

Bringing it all together

In this article, we explored how Long COVID continues to affect millions of people worldwide and introduced synbiotics as a targeted approach to support gut health and recovery. We also looked at the development of SIM01, a clinically designed synbiotic formula based on microbiome imbalances observed in COVID-19 patients.

Building on this foundation, a large-scale clinical trial published in The Lancet Infectious Diseases investigated the potential of SIM01 to relieve persistent Long COVID symptoms. Over six months, individuals who took SIM01 reported greater improvement in fatigue, memory loss, gastrointestinal discomfort, and poor concentration compared with those who received a placebo.

The study also found meaningful shifts in the gut microbiota, including restored microbial diversity and an increase in beneficial species. But how could supplementing with just three selected probiotic strains lead to broader improvement, including the growth of other native beneficial bacteria? The answer, as the research suggests, lies in the intelligent design of the synbiotic formula and a fascinating ecological process known as cross-feeding.

This mechanism works like a collaborative relay within the gut. The prebiotics in the SIM01 formula serve as the initial fuel, specifically nourishing the three introduced Bifidobacterium strains. As these probiotics consume the prebiotics, they produce beneficial compounds such as acetate and lactate. These compounds then become ideal fuel for other important native bacteria, including Faecalibacterium prausnitzii, a key producer of butyrate, which is a short-chain fatty acid closely linked to gut and immune health. In other words, the supplemented probiotics do not work in isolation. They help trigger a positive chain reaction that supports the wider gut ecosystem.

This finding highlights an important point: the gut is not a passive container, but a dynamic and interactive system. Effective microbiome support is not simply about adding good bacteria. It is about creating the right conditions for beneficial microbes to work together and thrive. While more research will continue to deepen our understanding, this study offers encouraging evidence that targeted gut microbiome support may play a meaningful role in Long COVID recovery, and that gut health may be more closely tied to systemic recovery than previously understood.

References

1. World Health Organization (WHO) [Internet]. WHO Coronavirus (COVID-19) Dashboard. Geneva: WHO; 2023 [cited 2025 Apr 17]. Available from: https://covid19.who.int/

2. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–15.

3. Centers for Disease Control and Prevention (CDC) [Internet]. Post-COVID conditions: information for healthcare providers. Atlanta (GA): CDC; 2023 [cited 2025 Apr 17]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html

4. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–46.

5. Zhang F, Lau RI, Liu Q, Su Q, Chan FKL, Ng SC. Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications. Nat Rev Gastroenterol Hepatol. 2023;20(5):323–37.

6. National Health Service (NHS) [Internet]. Long-term effects of coronavirus (Long COVID). London: NHS England; 2023 [cited 2025 Apr 17]. Available from: https://www.nhs.uk/conditions/covid-19/long-term-effects-of-covid-19-long-covid/

7. Hu J, Zhang L, Lin W, Tang W, Chan FKL, Ng SC. Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic. Aliment Pharmacol Ther. 2022;55(3):300-316. doi:10.1111/apt.16750.

8. Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalisation. Gastroenterology. 2020 Sep;159(3):944–955.e8. doi:10.1053/j.gastro.2020.05.048

9. Yeoh YK, Zuo T, Lui GCY, Zhang F, Liu Q, Li AYL, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021 Apr;70(4):698–706. doi:10.1136/gutjnl-2020-323020

10. Zuo T, Liu Q, Zhang F, Lui GCY, Tso EYK, Yeoh YK, et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021 Feb;70(2):276–284. doi:10.1136/gutjnl-2020-322294

11. Lau RI, Su Q, Lau ISF, Ching JYL, Wong MCS, Lau LHS, et al. A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2024 Mar;24(3):256–65. doi:10.1016/S1473-3099(23)00685-0